Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Franco Locatelli und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Here we report efficacy, pharmacokinetics, and safety data obtained in treatment‐naive, pediatric patients with newly diagnosed advanced MDS receiving azacitidine in the AZA‐JMML‐001 study. The primary endpoint was response rate (proportion of patients with complete response [CR], partial response [PR], or marrow CR, sustained for ≥4 weeks). Of the 10 patients enrolled, one had an unconfirmed marrow CR and none had confirmed responses after three cycles; the study was therefore closed after stage 1. Azacitidine was well tolerated. The lack of efficacy of azacitidine in pediatric patients with newly diagnosed advanced MDS highlights the need for effective new treatments in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy.
- Department of Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Germany.
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
- NCCS, Children's Health Ireland at Crumlin, Dublin, Ireland.
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
ORCID-Profile: Franco Locatelli, Karin Belander Strålin, Julián Sevilla, Marco Zecca, Charlotte M Niemeyer
Förderung
- Bristol Myers Squibb
Zitieren
APA
Locatelli, F., Strålin, K. B., Schmid, I., Sevilla, J., Smith, O. P., van den Heuvel-Eibrink, M. M., Zecca, M., Zwaan, C. M., Gaudy, A., Patturajan, M., Poon, J., Simcock, M., & Niemeyer, C. M. (2024). Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30931
Vancouver
Locatelli F, Strålin KB, Schmid I, Sevilla J, Smith OP, van den Heuvel-Eibrink MM, et al. Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30931
BibTeX
@article{Locatelli2024,
author = {Locatelli, Franco and Strålin, Karin Belander and Schmid, Irene and Sevilla, Julián and Smith, Owen P and van den Heuvel-Eibrink, Marry M and Zecca, Marco and Zwaan, Christian M and Gaudy, Allison and Patturajan, Meera and Poon, Jennifer and Simcock, Mathew and Niemeyer, Charlotte M},
title = {Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30931}
}
EUVIMED